2020.06
TWi's ANDA for Terbutaline Sulfate Tablets (equivalent to Brethine®) has been officially approved by US FDA

June 23, 2020 . TWi Pharmaceuticals, Inc. (TWi) today announced that its ANDA (Abbreviated New Drug Application) for Terbutaline Sulfate Tablets (equivalent to Brethine®) has been officially approved by US FDA. The Company will start the preparation for launch in the US market accordingly.

 

Terbutaline Sulfate Tablets are indicated for the prevention and reversal of bronchospasm in patients 12 years of age and older with asthma and reversible bronchospasm associated with bronchitis and emphysema. According to IQVIA data, the total sales of Terbutaline Sulfate Tablets in the US were approximately US $8 million for the 12 months ended April 2020.

 

About TWi Pharmaceuticals, Inc.
TWi Pharmaceuticals, Inc. is a leading specialty pharmaceutical company based in Taipei, Taiwan, focusing on the development of high barrier to entry generic prescription products ranging from oral controlled release dosage forms to novel drug delivery systems including the utilization of nanoparticles, transdermal, and polymeric oral delivery systems. Leveraging its internal research and development capabilities, together with operational flexibility, process development, manufacturing and regulatory expertise, TWi Pharmaceuticals concentrates on products and technologies that present significant barriers to entry or offer unparalleled market opportunities in the United States. For more information on TWi Pharmaceuticals and its fully owned US subsidiary, TWi Pharmaceuticals USA, Inc., please visit 
www.twipharma.com

 

 

 

Top